Jeff Carter

Mr Carter joined Actinogen in September 2020 and has more than 30 years of expertise in professional accounting, investment banking, corporate finance and commercial / strategic planning roles. He has served as a member of the board on a USA based company. He was the chief financial officer of the company until it’s move to the USA at the end of 2009. Since the beginning of 2000 he has served as chief financial officer and company secretary of various publicly listed healthcare and biotech companies. Prior to his move into the healthcare sector he also held senior positions with Coca Cola Amatil, Santos, Canadian Imperial Bank of Commerce and Touche Ross.

Mr Carter holds a Bachelor of Financial Administration (UNE) and a Master of Applied Finance (Macquarie University) and is a qualified Chartered Accountant.

Mr Carter is also the Chief Financial Officer of Amplia Therapeutics Limited (ASX:ATX) since 2013.

Jack Taylor

Jack joined Actinogen in February 2020, bringing a deep understanding of pharmaceutical science and a passion for novel drug discovery research. 

Jack obtained his Bachelor of Science in Neuroscience and Physiology at the University of Sydney in 2011 and a Master of Pharmacy at the University of Technology (UTS) in 2015. He recently completed his PhD at UTS in the laboratory of Cancer Cell Biology and Therapeutics.  Using a combination of molecular, imaging, and analytical techniques, Jack’s research focused on the biogenic pathways of extracellular vesicles. Specifically, his research discovered there are discrete molecular pathways that regulate extracellular vesicle biogenesis in malignant and non-malignant cells – identifying new potential strategies to circumvent multidrug resistance in cancer.

LinkedIn Profile: https://www.linkedin.com/in/jack-taylor-3589b4145

Miriam Roesner

Miriam has over 16 years of experience working in Biotechnology and CRO settings. Starting her career in Germany, she gained work experience in Germany and the UK; moving to Australia gave her the opportunity to work in a global context and gain expertise within the Asia-Pacific region, managing clinical trials with local and global clients.

Her experience covers a diversity of project management roles across multiple therapeutic areas in all stages of clinical development, as well as people management.

Miriam is responsible for implementing Actinogen’s clinical development plan for Xanamem, including CRO and vendor management, and overseeing Grant applications.

LinkedIn Profile: linkedin.com/in/miriam-roesner

Tamara Miller

Tamara joined Actinogen in September 2017, bringing with her over 18 years of international clinical research experience. Tamara has a Masters and Bachelor’s Degree in Biomedical Sciences, as well as a Diploma of Business and a Diploma of Project Management.

Tamara has lived and worked in the UK and the US whilst holding senior positions in clinical development, operations, and project management; Tamara’s background includes positions within Pharmaceutical and Biotechnology companies as well as for CROs, working across a multitude of therapeutic areas and managing all aspects of the drug development process.

As part of the Actinogen team, Tamara oversees and manages the overall clinical development process & strategy including clinical research, CMC & manufacturing, non-clinical, and regulatory operations for Xanamem.

LinkedIn Profile: linkedin.com/in/tamara-miller-72b3b911

Therese Russell

Therese is the Executive Assistant and Office Manager at Actinogen Medical. She joined the team in 2016, bringing with her over 20 years of experience in administrative and office management. Therese’s organisational abilities ensures the daily operations at Actinogen Medical run smoothly.

LinkedIn Profile: linkedin.com/in/therese-russell-b33b95127

Peter Webse

Mr Webse has over 26 years of company secretarial experience and is the managing director of Platinum Corporate Secretariat Pty Ltd, a company specialising in providing company secretarial, corporate governance, and corporate advisory services.

Peter attended Edith Cowan University of Western Australia to obtain his degree in Accounting and Finance. Peter is a highly experienced CPA and is a Fellow of the CPA Australia (FCPA). He is also a Fellow of the Governance Institute of Australia (FGIA), a Fellow of the Chartered Governance Institute (GCI), and a Member of the Australian Institute of Company Directors (MAICD).

Mr Webse is also a non-executive director of Cynata Therapeutics Limited.

LinkedIn Profile: linkedin.com/in/peter-webse-0489b513

Dr. Bill Ketelbey

Dr Ketelbey has more than 30 years’ experience in the healthcare, biotech and pharmaceutical industries, including senior medical and management roles in the Asia Pacific Region with global pharmaceutical company Pfizer.

Dr Ketelbey has a solid track record of product development over his years in the industry leading to the successful registration, launch and commercialisation of numerous market leading medicines in a broad range of therapeutic areas, including in Alzheimer’s disease. Dr Ketelbey led the local clinical development, and was involved in the commercialisation, of Aricept™ (donepezil), the market-leading Alzheimer’s disease therapy.

Dr Ketelbey is a medical graduate from the University of the Witwatersrand, South Africa and a Fellow of the Faculty of Pharmaceutical Physicians from the Royal College of Physicians in the United Kingdom. He also has an MBA from Macquarie Graduate School of Management, Australia, and is a Graduate of the Australian Institute of Company Directors.

Dr. Ketelbey is also a Non-Executive Director of the Westmead Institute of Medical Research (WIMR) and chairs the IP and Commercialisation Committee of WIMR.

LinkedIn Profile: linkedin.com/in/bill-ketelbey-0032098a

Twitter: @BillKetelbey https://twitter.com/billketelbey